Abstract
Dimeric peptide-based inhibitors of postsynaptic density-95 (PSD-95) can reduce ischemic brain damage and inflammatory pain in rodents. To modify the pharmacokinetic profile we designed a series of fatty acid linked dimeric ligands, which potently inhibits PSD-95 and shows improved in vitro blood plasma stability. Subcutaneous administration in rats showed extended stability and sustained release of these ligands. This can facilitate new pharmacological uses of PSD-95 inhibitors and further exploration of PSD-95 as a drug target.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Journal of Medicinal Chemistry |
Vol/bind | 58 |
Sider (fra-til) | 1575-1580 |
Antal sider | 6 |
ISSN | 0022-2623 |
DOI | |
Status | Udgivet - 12 feb. 2015 |